BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Gastric and GEJ cancer clinical trials and catalysts
Active industry-sponsored trials on ClinicalTrials.gov for gastric cancer: 315 (205 sponsors; 40 newly posted in the last 180 days, 12 stopped in the last 180 days; 19 new-entrant sponsors). Momentum score 13.7, rank 49 of 91 on the disease-area ranking. As of 2026-11-18.
Phase distribution: Early Phase 1 5, Phase 1 105, Phase 2 123, Phase 3 46, Phase 4 3, N/A 33.
Most active sponsors, by phase
| Sponsor | Active trials | By phase | New (window) | Upcoming readouts |
|---|---|---|---|---|
| AstraZeneca AZN | 25 | P2 16, NA 2, P3 5, P1 2 | 3 | 5 |
| Astellas Pharma Global Development, Inc. | 10 | P3 4, P1 1, P2 4, P4 1 | 2 | 1 |
| RemeGen Co., Ltd. | 5 | P3 4, P2 1 | 0 | 1 |
| Daiichi Sankyo | 5 | NA 1, P3 2, P2 2 | 0 | 0 |
| Akeso | 3 | NA 1, P3 2 | 1 | 0 |
| Jiangsu HengRui Medicine Co., Ltd. | 3 | P3 2, P2 1 | 0 | 0 |
| Ono Pharmaceutical Co., Ltd. | 3 | P2 1, P3 2 | 1 | 0 |
| Shanghai JMT-Bio Inc. | 3 | P3 2, P2 1 | 0 | 0 |
| Bristol-Myers Squibb BMY | 7 | NA 3, P1 1, P2 2, P3 1 | 1 | 1 |
| Novartis Pharmaceuticals NVS | 4 | P1 2, NA 1, P3 1 | 3 | 0 |
| Pfizer PFE | 4 | P1 2, P4 1, P3 1 | 2 | 1 |
| Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 4 | P2 3, P3 1 | 0 | 0 |
| Jazz Pharmaceuticals JAZZ | 3 | P3 1, NA 1, P2 1 | 1 | 1 |
| Merck Sharp & Dohme LLC MRK | 3 | P4 1, P2 1, P3 1 | 1 | 0 |
| Advanced Accelerator Applications | 2 | P2 1, P3 1 | 0 | 0 |
| CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2 | P3 1, P2 1 | 0 | 1 |
| ITM Solucin GmbH | 2 | P3 1, P1 1 | 0 | 0 |
| RayzeBio, Inc. | 2 | P1 1, P3 1 | 0 | 2 |
| Transcenta Therapeutics (Hangzhou) Co., Ltd. | 2 | P3 1, P2 1 | 0 | 0 |
| Biokin (Shanghai) Biopharmaceutical Co., Ltd. | 1 | P3 1 | 0 | 0 |
| Camurus AB | 1 | P3 1 | 0 | 0 |
| FutureGen Biopharmaceutical (Beijing) Co., Ltd | 1 | P3 1 | 0 | 1 |
| GE Healthcare | 1 | P3 1 | 0 | 0 |
| LaNova Medicines Limited | 1 | P3 1 | 0 | 0 |
| Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. | 1 | P3 1 | 0 | 0 |
Recently stopped trials
- NCT06882746 Boehringer Ingelheim - terminated: Sponsor decision A Study to Test Different Doses of BI 765049 in People With Advanced Cancer of the Colon, Rectum, Stomach, or Pancreas
- NCT04868877 Merus B.V. - terminated: The Sponsor terminated the trial early for strategic business reasons. This isn't related to any safety/efficacy/clinical activity/benefit-r Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Soli
- NCT06714617 SystImmune Inc. - terminated: The decision is based only on the Sponsor's internal portfolio prioritization and resource management considerations and is not due to the i Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors
- NCT05111626 Amgen - terminated: Study was terminated by sponsor Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advan
- NCT05188209 Lepu Biopharma Co., Ltd. - terminated: Study terminated due to sponsor decision A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Advanced Gastric Cancer.
- NCT05572684 NextCure, Inc. - terminated: Following completion of Phase 1b, the Sponsor decided not to initiate Part 2 of the trial. A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Meta
- NCT03281369 Hoffmann-La Roche - terminated: The study was closed because the sponsor decided not to continue the development of certain treatment combinations. A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metasta
- NCT05322577 Amgen - terminated: Sponsor Decision A Study Evaluating Bemarituzumab in Combination With Other Anti-cancer Therapies in Subjects With Previously Untreated A
- NCT04348643 Chongqing Precision Biotech Co., Ltd - withdrawn: The sponsor requested to terminate the study. Safety and Efficacy of CEA-Targeted CAR-T Therapy for Relapsed/Refractory CEA+ Cancer
- NCT06585488 BeOne Medicines - terminated: The Sponsor has made the decision to terminate this study due to the lack of promising efficacy, internal prioritization, and highly competi A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Met
- NCT05514717 Day One Biopharmaceuticals, Inc. - terminated: Development discontinued. A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2
- NCT04458259 Pfizer - terminated: Pfizer has made an internal business decision to not continue further development of PF-07265807. This decision was not due to major safety Study of PF-07265807 in Participants With Metastatic Solid Tumors.
Upcoming trial readouts (next 90 days)
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-12 est. | P1/P2 | Rottapharm Biotech | NCT05205330 Vorbipiprant (CR6086) / Balstilimab (AGEN2034) Combination in Stage IV Refractory pMMR - MSS CRC, and Other Metastatic GI Cancers | Refractory Metastatic Colorectal Cancer; Solid Tumor; Metastatic Microsatellite-stable Colorectal Ca | active not recruiting | 107 |
| 2026-12 est. | P2 | Sichuan Baili Pharmaceutical Co., Ltd. | NCT06008054 A Study of SI-B003, BL-B01D1+SI-B003 and BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Esophageal Cancer, Gastric Cancer, Co | Esophageal Cancer; Gastric Cancer; Colorectal Cancer | recruiting | 376 |
| 2026-12 est. | P2/P3 | RemeGen Co., Ltd. | NCT06221748 DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therap | Gastric Cancer; Gastroesophageal Junction Adenocarcinoma | recruiting | 90 |
| 2026-12 est. | P1/P2 | 858 Therapeutics, Inc. | NCT06395519 A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies | Advanced or Metastatic Solid Tumors; Breast Cancer; Ovarian Cancer; Prostate Cancer; Epithelial Ovar | recruiting | 120 |
| 2026-12 est. | P2 | Qilu Pharmaceutical Co., Ltd. | NCT06942767 Combination of QLS31905, QL2107 and Chemotherapy as First-line Therapy in CLDN18.2-positive Unresectable Locally Advanced or Metastatic Gastric or Gastroesophag | Gastric Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma | not yet recruiting | 100 |
| 2026-12 est. | P1/P2 | One-carbon Therapeutics AB | NCT07151040 Phase 1/2 Study to Evaluate TH9619 in the Treatment of Advanced Solid Tumors | Solid Tumor; Colorectal Cancer (CRC); Squamous Cell Carcinoma of Head and Neck; Non-Small Cell Lung | recruiting | 43 |
| 2026-12 est. | P2 | Shenyang Sunshine Pharmaceutical Co., LTD. | NCT07233850 A Phase II Clinical Study Evaluating SSGJ-706 in Combination Therapy for Advanced Gastrointestinal Cancers | Gastric/Gastroesophageal Junction Adenocarcinoma; Metastatic Colorectal Cancer (CRC); Pancreatic Duc | not yet recruiting | 300 |
| 2026-12-22 est. | P2 | Healthgen Biotechnology Corp. | NCT07893600 Efficacy and Safety of OsrhCT Before Upper Endoscopy on Improving Visualization of the Gastric Mucosa. | Gastric Mucosal Lesion | not yet recruiting | 40 |
| 2026-12-30 est. | P2 | Teclison Ltd. | NCT03259867 Combination of TATE and PD-1 Inhibitor in Liver Cancer | Hepatocellular Carcinoma; Gastric Cancer | recruiting | 54 |
| 2026-12-30 est. | P3 | AskGene Pharma, Inc. | NCT06206733 ASKB589 in Combination With CAPOX and PD-1 Inhibitor in Patients With Advanced or Metastatic GC/GEJ Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma; Gastric Adenocarcinoma | active not recruiting | 780 |
| 2026-12-30 est. | P3 | Innovent Biologics (Suzhou) Co. Ltd. | NCT06238843 A Multicenter, Phase 3 Study of IBI343 Monotherapy Versus Treatment of Investigator's Choice in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, | Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma | active not recruiting | 464 |
| 2026-12-30 est. | P1/P2 | Astellas Pharma Global Development, Inc. | NCT06792435 XNW27011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies. | Pancreatic Adenocarcinoma Metastatic; Lung Cancer (NSCLC); Ovarian Cancer; Colorectal Cancer Metasta | active not recruiting | 240 |
| 2026-12-31 est. | P1/P2 | OncoC4, Inc. | NCT04140526 Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC | Non Small Cell Lung Cancer; Advanced Solid Tumor; Metastatic Melanoma; Metastatic Head and Neck Carc | active not recruiting | 733 |
| 2026-12-31 est. | P1/P2 | BicycleTx Limited | NCT04180371 Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression | Advanced Solid Tumor Historically Known for High EphA2 Expression; Urothelial Cancer; Ovarian Cancer | active not recruiting | 288 |
| 2026-12-31 est. | P1/P2 | Chimeric Therapeutics | NCT06055439 A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy | Neuroendocrine Tumors; Colorectal Cancer; Gastric Cancer | active not recruiting | 135 |
| 2026-12-31 est. | P2 | Jazz Pharmaceuticals JAZZ | NCT06695845 A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors | Breast Cancer; Gastric Cancer; Esophageal Cancer; Gastroesophageal Cancer; Colorectal Cancer; Endome | recruiting | 200 |
| 2026-12-31 est. | P2 | Beijing Biostar Pharmaceuticals Co., Ltd. | NCT06730581 Utidelone Capsule Monotherapy for Patients with Advanced Solid Tumors | Gastric Cancer Adenocarcinoma Metastatic; Ovarian Cancer; Bile Duct Cancer | not yet recruiting | 100 |
| 2027-01-01 est. | P1/P2 | Second Life Therapeutics | NCT07341737 SL-28 for Advanced Solid Tumours | Head & Neck Cancer; Pancreas Carcinoma; Pancreas Cancer, Metastatic; Lung Adenocarcinoma; Lung Cance | recruiting | 60 |
| 2027-01-11 est. | P3 | FutureGen Biopharmaceutical (Beijing) Co., Ltd | NCT06177041 M108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Advanced Unresectable or | Locally Advanced Unresectable or Metastatic Gastric Cancer; Locally Advanced Unresectable or Metasta | recruiting | 486 |
| 2027-02 est. | P1/P2 | Lumicell, Inc. | NCT02584244 Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers | Colorectal Cancer; Pancreatic Cancer; Esophageal Cancer; Gastric Cancer | active not recruiting | 66 |
| 2027-02-09 est. | P2 | Aston Sci. Inc. | NCT05771584 Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Gastric Cancer | Gastric Cancer | active not recruiting | 24 |
| 2027-02-10 est. | P2 | AstraZeneca AZN | NCT06271837 A Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing Tumors | Advanced Solid Tumors (Excluding Gastric Cancer and Breast Cancer) | active not recruiting | 127 |
Readouts in the last 180 days
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11-17 est. | P2 | AstraZeneca AZN | NCT06219941 AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2 | Gastric Cancer; Gastroesophageal Junction Cancer; Biliary Tract Cancer; Pancreatic Ductal Adenocarci | recruiting | 226 |
| 2026-11 est. | P3 | Akeso | NCT06341335 A Study of AK104/Placebo Plus AK109/Placebo And Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma | Gastric and Gastroesophageal Junction Adenocarcinoma | recruiting | 506 |
| 2026-10-01 | P1/P2 | Merus B.V. | NCT04868877 Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination | Non-Small Cell Lung Cancer Metastatic; Gastric Cancer; Esophageal Squamous Cell Carcinoma; Head and | terminated | 194 |
| 2026-10 est. | P2 | Sichuan Baili Pharmaceutical Co., Ltd. | NCT06423885 A Study of BL-M07D1 Combination Therapy in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocar | HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma | active not recruiting | 64 |
| 2026-09-30 est. | P2 | Convalife (Shanghai) Co., Ltd. | NCT06374888 Nilatinib Maleate Tablets Combined With Capecitabine in the Treatment of HER2-positive Advanced Esophageal/Esophagogastric Junction/Gastric Adenocarcinoma With | Her2-positive Advanced Esophageal/Esophagogastric Junction/Gastric Adenocarcinoma With Brain Metasta | not yet recruiting | 28 |
| 2026-08-31 est. | P3 | Daiichi Sankyo | NCT04704934 Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-C | Gastric Cancer, Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma | active not recruiting | 490 |
| 2026-08-26 est. | P1/P2 | Shanghai Runshi Pharmaceutical Technology Co., Ltd | NCT06577376 A PhaseⅠ/Ⅱ Study of Simmitinib or Irinotecan Liposomes Combined With DP303c in Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma | Localized Advanced or Metastatic Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma; | not yet recruiting | 252 |
| 2026-08-14 | P2 | AstraZeneca AZN | NCT07143604 A Study to Investigate the Effects of AZD0901 Monotherapy in Adult Participants With 2L+ Advanced or Metastatic Gastric or GEJ Adenocarcinoma Expressing CLDN18. | Gastric Cancer; Gastroesophageal Junction Cancer | active not recruiting | 33 |
| 2026-08-03 est. | P2 | Catalysis SL | NCT07179237 Efficacy of Carminal in Helicobacter Pylori Gastritis | H Pylori Gastritis; H Pylori Infection; H Pylori Eradication; Gastritis Associated With Helicobacter | recruiting | 80 |
| 2026-08 est. | P2 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | NCT07110571 A Trial of Adebrelimab Plus (SHR-A1811/SHR-A1904 With Chemotherapy) or SHR-8068 as Treatment for Gastric/GEJ Cancer | Gastric Cancer; Gastroesophageal-junction Cancer | recruiting | 200 |
| 2026-07-31 est. | P1/P2 | Idience Co., Ltd. | NCT04725994 Study to Assess the Safety, Tolerability, and Efficacy of IDX-1197 in Combination With XELOX or Irinotecan in Patients With Advanced Gastric Cancer | Gastric Cancer | active not recruiting | 87 |
| 2026-07-15 | P3 | Jazz Pharmaceuticals JAZZ | NCT05152147 A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal | Gastric Neoplasms; Gastroesophageal Adenocarcinoma; Esophageal Adenocarcinoma | active not recruiting | 920 |
| 2026-06-02 | P1/P2 | Sensei Biotherapeutics, Inc. | NCT05864144 A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors | Solid Tumor, Adult; Advanced Solid Tumor; Head and Neck Cancer; Breast Cancer; Colon Cancer; Pancrea | completed | 98 |
| 2026-06-01 est. | P3 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | NCT06296706 A Clinical Study of Docetaxel for Injection (Albumin-bound) in Patients With Gastric Cancer | Gastric Cancer | recruiting | 630 |
| 2026-05-31 | P3 | AstraZeneca AZN | NCT06346392 AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Ad | Gastric Cancer; Gastroesophageal Junction Cancer | active not recruiting | 594 |
Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "gastric cancer"); readouts matched by condition text. Registry counts only; not a forecast.
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.